Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longidaze plus tamsulosin in benign prostatic hyperplasia
NCT06568718Completed
- Sponsor
- Petrovax Pharm
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Polymer-based Nanoparticles, Therapeutic Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of bovhyaluronidase azoximer in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Petrovax Pharm. Primary endpoint: International Prostate Symptom at 130 days. Started Mar 2023; status: completed.
02
Drugs
bovhyaluronidase azoximer
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT06568718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568718.